BiotechTube
SurgiMab

SurgiMab

Paris, France· Est.
surgimab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SurgiMab is a French biotech pioneer in near-infrared fluorescence-guided surgery and diagnostics. Its core platform conjugates tumor-targeting monoclonal antibodies with fluorescent dyes to illuminate cancerous tissue during procedures, enabling surgeons to achieve more complete resections. The company's lead asset, SGM-101, targets Carcinoembryonic Antigen (CEA) and is in Phase II trials for pancreatic cancer, with demonstrated utility in colorectal and lung cancers. SurgiMab's mission is to enhance cancer care through real-time visualization, aiming to reduce recurrence and improve patient outcomes.

Oncology

Technology Platform

Antibody-fluorophore conjugates for near-infrared (NIR) fluorescence imaging. The platform uses tumor-targeting monoclonal antibodies linked to fluorescent dyes to enable real-time visualization of cancer cells during surgery or endoscopic procedures.

Opportunities

The significant unmet need for improved surgical precision in oncology, with high rates of positive margins, creates a large and growing market for fluorescence-guided surgery.
The platform's adaptability to target different tumor antigens allows for expansion into numerous solid tumor types, moving beyond the initial CEA-focused program.

Risk Factors

Clinical development risks, including failure to demonstrate efficacy in pivotal trials.
Intense competition in the fluorescence imaging space from both large medtech firms and other biotechs.
Future dependency on raising significant capital to fund operations and commercialization as a pre-revenue company.

Competitive Landscape

SurgiMab operates in the competitive fluorescence-guided surgery market, competing with companies like On Target Laboratories (OTL38 for lung cancer), ImaginAb, and Quest Medical Imaging. Large medical device companies (e.g., Stryker, Karl Storz) are also integrating fluorescence capabilities into their surgical systems, though often with non-targeted dyes like indocyanine green (ICG).

More companies in Diagnostics & Precision Medicine →More companies in France →